Postural Orthostatic Tachycardia Syndrome (POTS)
14
5
7
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (14)
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
aVNT in POTS - Pilot
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
POLish Registry of CArdioneuroablation and CArdioneuromodulation
Programming Aquatic Therapy for POTS
The Renin-Aldosterone Axis in Postural Tachycardia Syndrome
Tragus Stimulation for POTS Treatment
POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS
Effects of Auricular Vagus Nerve Stimulation Combined With Slow-paced Breathing on Individuals With Postural Orthostatic Tachycardia Syndrome.
Auto-immune Contribution in Symptom-based Sensory and Autonomic Disorders
Counterpressure Maneuvers in Postural Orthostatic Tachycardia Syndrome
Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS
Abdominal and Lower Extremity Compression During Tilt Table Testing in Adolescent POTS Patients